Tizanidine Tablets (Dr. Reddy's) – Labeling Issue (2013)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Tizanidine Tablets USP, 4 mg, 150-count tablets per bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachepally - 500 090 India; NDC 55111-180-15.
Brand
Dr. Reddy'S Laboratories
Lot Codes / Batch Numbers
Lot #: C208625, C208984, C209113, C209369, Exp 09/15, and C209680, Exp 10/15.
Products Sold
Lot #: C208625, C208984, C209113, C209369, Exp 09/15; and C209680, Exp 10/15.
Dr. Reddy'S Laboratories is recalling Tizanidine Tablets USP, 4 mg, 150-count tablets per bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratori due to Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026